贝伐珠单抗联合紫杉醇与卡铂治疗晚期非小细胞肺癌患者的效果  

Effects of Bevacizumab combined with Paclitaxel and Carboplatin in treatment of advanced non-small cell lung cancer

作　　者：宁尚福 林才华[1] 骆明光[1] 肖晓高 杨勇 NING Shangfu;LIN Caihua;LUO Mingguang;XIAO Xiaogao;YANG Yong(Department of Oncology of Wuchuan People’s Hospital,Zhanjiang 524500 Guangdong,China)

机构地区：[1]吴川市人民医院肿瘤科,广东湛江524500

出　　处：《中国民康医学》2022年第23期39-42,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察贝伐珠单抗联合紫杉醇与卡铂治疗晚期非小细胞肺癌(NSCLC)患者的效果。方法:选取2018年3月至2020年5月该院收治的150例NSCLC患者进行前瞻性研究,根据随机数字表法分为对照组75例及观察组75例。对照组给予常规TP方案(紫杉醇与卡铂)化疗,观察组在对照组基础上联合贝伐珠单抗治疗,比较两组临床疗效、治疗前后血清生长因子[碱性成纤维细胞生长因子(bFGF)和血管内皮生长因子(VEGF)]水平、肿瘤标志物[细胞角蛋白19片段抗原(CYFRA21-1)、癌胚抗原(CEA)及糖类抗原125(CA125)]水平,以及不良反应发生率。结果:观察组客观缓解率为73.33%(55/75),高于对照组的57.33%(43/75),差异有统计学意义(P<0.05);治疗4个周期后,观察组血清bFGF、VEGF、CYFRA21-1、CEA及CA125水平均低于对照组,差异有统计学意义(P<0.05);两组皮肤过敏、骨髓抑制、肝肾功能异常、胃肠道反应等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:贝伐珠单抗联合紫杉醇、卡铂治疗晚期NSCLC患者可提高客观缓解率,显著降低血清bFGF、VEGF水平与肿瘤标志物水平,且未增高不良反应发生率。Objective:To observe the efficacy of bevacizumab combined with paclitaxel and carboplatin in the treatment of advanced nonsmall cell lung cancer(NSCLC).Methods:A total of 150 NSCLC patients admitted to the hospital from March 2018 to May 2020 were selected for prospective study,and were divided into control group(75 cases)and observation group(75 cases)according to random number table method.The control group was given conventional TP regimen(Paclitaxel and Carboplatin)chemotherapy,while the observation group was treated with Bevacizumab on the basis of that of the control group.The clinical efficacy,the serum growth factor levels[basic fibroblast growth factor(bFGF)and vascular endothelial growth factor(VEGF)],the tumor marker levels[cytokeratin 19 fragment antigen(CYFRA21-1),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)],and incidence of adverse reactions were observed in the two groups before and after the treatment.Results:The objective remission rate of the observation group was 73.33%(55/75),which was higher than 57.33%(43/75)of the control group,and the difference was statistically significant(P<0.05).After 4 cycles of treatment,the levels of serum bFGF,VEGF,CYFRA21-1,CEA and CA125 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there were no significant differences in the incidence of adverse reactions such as skin allergy,bone marrow suppression,liver and kidney dysfunction and gastrointestinal reactions between the two groups(P>0.05).Conclusions:Bevacizumab combined with Paclitaxel and Carboplatin in the treatment of THE patients with advanced NSCLC can improve the objective remission rate and significantly reduce the levels of serum bFGF,VEGF and tumor markers without increasing the incidence of adverse reactions.

关 键 词：贝伐珠单抗 非小细胞肺癌 卡铂 紫杉醇 碱性成纤维细胞生长因子 血管内皮生长因子 

分 类 号：R734.2[医药卫生—肿瘤]